A pharmaceutical composition for therapeutically treating prostate cancer, the pharmaceutical composition containing N-Ä6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinylÜ-2-p henylethenesulfoneamide or a pharmaceutically acceptable salt thereof as the effective component.